Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Parallel, Multi-Center Phase IV Study to Compare of the Efficacy and Safety of Lipilou 20 mg and Lipilou 10 mg in High-risk Patients With Hypercholesterolemia(PEARL Study)

NCT04511000 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT04511000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Parallel, Multi-Center Phase IV Study to Compare of the Efficacy and Safety of Lipilou 20 mg and Lipilou 10 mg in High-risk Patients With Hypercholesterolemia(PEARL Study)
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 4
Overall status
Completed
Start date
October 11, 2017
Completion date
May 20, 2019
Enrollment
250 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia